Polyrizon files patent for nasal drug delivery tech

Published 30/01/2025, 12:02
Polyrizon files patent for nasal drug delivery tech

Raanana, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a biotech firm in the development stage, has filed a divisional patent application in Israel for its Trap & Target (NYSE:TGT) (T&T) platform technology. This move, announced today, aims to protect the company’s advanced intranasal drug delivery system designed to improve medication efficacy by increasing residence time and contact with mucosal tissues.

The T&T technology focuses on enhancing the bioavailability of active pharmaceutical ingredients (APIs), offering a controlled release, and preventing dripping from the nasal cavity. It utilizes biodegradable components and is versatile enough to be compatible with various drug types, including small molecules and antibodies.

Polyrizon’s CEO Tomer Izraeli believes that the T&T platform could transform intranasal drug delivery, potentially improving efficacy and safety for a wide range of medications. The platform leverages the nasal cavity’s rich vascularization for both local and systemic drug delivery, which could be beneficial for treating respiratory conditions, central nervous system disorders, and other medical needs.

The divisional patent application complements Polyrizon’s recent U.S. patent application, which covers aspects of its two core technologies: Capture and Contain (C&C™) and T&T. The C&C platform is designed to form a barrier against airborne threats such as allergens and viruses by adhering to the nasal mucosa.

Polyrizon specializes in developing medical device hydrogels in the form of nasal sprays, which aim to create a barrier against viruses and allergens. The company is advancing its C&C hydrogel technology to enhance bioadhesion and retention for intranasal drug delivery.

This press release contains forward-looking statements regarding the company’s intellectual property protection efforts and the potential of its technologies to revolutionize respiratory health and drug delivery. However, there are no guarantees that any patent will be issued or, if issued, that it will be advantageous to the company. InvestingPro analysis highlights several risk factors, including high price volatility and weak gross profit margins. Subscribers to InvestingPro can access additional insights and metrics to better evaluate the company’s potential. These statements are based on current management expectations and are subject to risks and uncertainties that could cause actual results to differ materially.

The filing of this patent application represents Polyrizon’s ongoing commitment to securing its intellectual property and advancing its technology to address healthcare challenges. The information is based on a press release statement from Polyrizon Ltd.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.